Deutsche Bank Comments on How Biogen Idec May be Affected by Tecfidera IMS Data

In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating and $340.00 price target on

. In the report, Deutsche Bank noted, “Our calculations on IMS data for Tecfidera for week ending 11/22 indicate strong Tecfidera at $363M-$365M in Q4'13. For FY 2013, our calculations based on IMS data indicate Tecfidera US sales at $839M-$841M. Consensus is expecting 4Q sales at $338M while 2013 sales at $807M in the US. Please ask for our detailed analysis of IMS scripts. Trx were down 1% at 4,967 vs. 5,026 last wk, Nrx were down 3% at 1,805 vs. 1,862 last week.” Biogen Idec closed on Wednesday at $293.83.